{"id":"aldara-imiquimod","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Local skin irritation (erythema, erosion)"},{"rate":"20-40","effect":"Pruritus"},{"rate":"20-30","effect":"Burning sensation"},{"rate":"20-40","effect":"Scabbing/crusting"},{"rate":"5-10","effect":"Flu-like symptoms"},{"rate":"5-10","effect":"Lymphadenopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imiquimod binds to TLR7 on immune cells, triggering production of interferon-alpha and other cytokines that enhance antiviral and anti-tumor immunity. This immune activation helps the body's own defenses clear human papillomavirus (HPV) infections and eliminate abnormal skin cells. The drug is applied topically, concentrating immune stimulation at the site of lesions.","oneSentence":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat viral infections and skin cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:39.992Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Genital warts (external)"},{"name":"Actinic keratosis"},{"name":"Superficial basal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT03276832","phase":"EARLY_PHASE1","title":"Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-12-20","conditions":"Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7","enrollment":7},{"nctId":"NCT05055050","phase":"PHASE1","title":"A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-01-24","conditions":"Bladder Cancer, Bladder","enrollment":10},{"nctId":"NCT07210775","phase":"PHASE1, PHASE2","title":"Topical Imiquimod Treatment of Oral Dysplasia","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2025-10-01","conditions":"Oral Dysplasia, Leukoplakia Oral, Leukoplakia","enrollment":20},{"nctId":"NCT01795313","phase":"PHASE1","title":"Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod","status":"TERMINATED","sponsor":"James Felker","startDate":"2012-08","conditions":"Ependymoma","enrollment":23},{"nctId":"NCT02600949","phase":"PHASE1","title":"Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-11","conditions":"Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":117},{"nctId":"NCT05212246","phase":"PHASE3","title":"Basal Cell Carcinoma Chemoprevention Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Basal Cell Carcinoma","enrollment":1630},{"nctId":"NCT05375903","phase":"PHASE1","title":"A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"UroGen Pharma Ltd.","startDate":"2022-06-01","conditions":"Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder","enrollment":51},{"nctId":"NCT03534947","phase":"PHASE2","title":"A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Melanoma Institute Australia","startDate":"2019-07-23","conditions":"Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified, Skin Cancer","enrollment":16},{"nctId":"NCT07077616","phase":"EARLY_PHASE1","title":"Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2025-07-01","conditions":"Glioma","enrollment":29},{"nctId":"NCT03073967","phase":"PHASE3","title":"Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects","status":"COMPLETED","sponsor":"AiCuris Anti-infective Cures AG","startDate":"2017-05-08","conditions":"HSV Infection","enrollment":158},{"nctId":"NCT07251413","phase":"PHASE1, PHASE2","title":"Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Instituto Oncológico Dr Rosell","startDate":"2025-10-22","conditions":"Cutaneous Basal Cell Carcinoma","enrollment":18},{"nctId":"NCT04808245","phase":"PHASE1","title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-02-15","conditions":"Newly Diagnosed H3-mutated Glioma","enrollment":15},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT02059499","phase":"PHASE3","title":"Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2015-12-28","conditions":"Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection","enrollment":91},{"nctId":"NCT03370406","phase":"PHASE1","title":"Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC","status":"RECRUITING","sponsor":"Melissa Pugliano-Mauro","startDate":"2018-08-03","conditions":"Carcinoma, Squamous Cell","enrollment":30},{"nctId":"NCT06973473","phase":"","title":"Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts:Randomized Comparative Trial.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-07-01","conditions":"Warts","enrollment":60},{"nctId":"NCT03196180","phase":"EARLY_PHASE1","title":"Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-15","conditions":"Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2","enrollment":13},{"nctId":"NCT06840470","phase":"PHASE4","title":"Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-03-11","conditions":"Sebaceous Hyperplasia","enrollment":40},{"nctId":"NCT01926496","phase":"PHASE4","title":"Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09-11","conditions":"Actinic Keratosis (AK)","enrollment":485},{"nctId":"NCT02889159","phase":"PHASE1","title":"Immunologic Profile of Chronically Photodamaged Skin","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2016-06-06","conditions":"Photoaged Skin, Normal Skin","enrollment":40},{"nctId":"NCT06356012","phase":"PHASE4","title":"Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod","status":"RECRUITING","sponsor":"Barretos Cancer Hospital","startDate":"2024-04-02","conditions":"HSIL, High-Grade Squamous Intraepithelial Lesions, Vaginal Microbiome, Biomarkers","enrollment":96},{"nctId":"NCT02078648","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2014-05","conditions":"Adult Brain Glioblastoma, Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT04883645","phase":"EARLY_PHASE1","title":"Neoadjuvant Imiquimod Immunotherapy for Oral Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2022-04-28","conditions":"Oral Squamous Cell Carcinoma","enrollment":16},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT06686043","phase":"PHASE2","title":"HPV Vaccine, Imiquimod, and Metformin Combination Trial","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2024-08-23","conditions":"Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma","enrollment":85},{"nctId":"NCT04809662","phase":"","title":"Comparing Immune Responses to Topical Imiquimod","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2021-03-16","conditions":"Actinic Keratoses","enrollment":6},{"nctId":"NCT05641545","phase":"PHASE1","title":"IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients","status":"TERMINATED","sponsor":"SLK Kliniken Heilbronn GmbH","startDate":"2022-10-17","conditions":"Advanced Renal Cell Carcinoma","enrollment":1},{"nctId":"NCT02135419","phase":"PHASE3","title":"Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2014-09-24","conditions":"Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection","enrollment":4446},{"nctId":"NCT01803152","phase":"PHASE1","title":"Dendritic Cell Vaccine for Children and Adults With Sarcoma","status":"COMPLETED","sponsor":"Macarena De La Fuente, MD","startDate":"2014-01-06","conditions":"Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma","enrollment":19},{"nctId":"NCT02394132","phase":"PHASE3","title":"Radiotherapy or Imiquimod in Complex Lentigo Maligna","status":"COMPLETED","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2015-08-31","conditions":"Lentigo Maligna","enrollment":126},{"nctId":"NCT00799110","phase":"PHASE2","title":"Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-08","conditions":"Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer","enrollment":23},{"nctId":"NCT06411106","phase":"NA","title":"Deep Phenotyping of Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2024-06","conditions":"Cutaneous Lupus Erythematosus","enrollment":40},{"nctId":"NCT02864147","phase":"PHASE2","title":"Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)","status":"COMPLETED","sponsor":"Yale University","startDate":"2016-07","conditions":"Cervical Intraepithelial Neoplasia, Cervical Dysplasia","enrollment":134},{"nctId":"NCT06252857","phase":"","title":"Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2024-04-22","conditions":"Basal Cell Carcinoma","enrollment":142},{"nctId":"NCT05838599","phase":"EARLY_PHASE1","title":"Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-07-24","conditions":"Mycosis Fungoides","enrollment":25},{"nctId":"NCT06305910","phase":"PHASE1","title":"CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults","status":"RECRUITING","sponsor":"OX2 Therapeutics","startDate":"2024-03-15","conditions":"Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma","enrollment":24},{"nctId":"NCT06170983","phase":"NA","title":"Skin Inflammation and PK of Azithromycin","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-01-01","conditions":"Skin Infection","enrollment":36},{"nctId":"NCT03559413","phase":"PHASE1, PHASE2","title":"Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL","status":"COMPLETED","sponsor":"University Children's Hospital Tuebingen","startDate":"2016-06","conditions":"Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults","enrollment":30},{"nctId":"NCT06052696","phase":"PHASE4","title":"Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-12-01","conditions":"Vulvar HSIL, HPV","enrollment":500},{"nctId":"NCT05405270","phase":"","title":"Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment","status":"RECRUITING","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2022-06-01","conditions":"Cervical High Grade Squamous Intraepithelial Lesion, Cervical Intraepithelial Neoplasia Grade 2/3, CIN 2/3","enrollment":410},{"nctId":"NCT00788164","phase":"PHASE1","title":"Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-11","conditions":"Cervical Cancer, Precancerous Condition, HPV Disease","enrollment":75},{"nctId":"NCT03180684","phase":"PHASE2","title":"Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2017-08-31","conditions":"Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN)","enrollment":33},{"nctId":"NCT00314756","phase":"PHASE4","title":"Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2005-03","conditions":"Basal Cell Carcinoma","enrollment":15},{"nctId":"NCT05740969","phase":"PHASE2","title":"Gene and Protein Expression Profiles After Treatment of Actinic Keratoses","status":"UNKNOWN","sponsor":"Ismail Gögenur","startDate":"2023-02-01","conditions":"Actinic Keratoses","enrollment":48},{"nctId":"NCT05468606","phase":"EARLY_PHASE1","title":"Coadministration of GA2 Sporozoites With Adjuvants","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-02-03","conditions":"Malaria,Falciparum","enrollment":45},{"nctId":"NCT01720407","phase":"PHASE3","title":"Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-12","conditions":"Lentigo Maligna Melanoma (Head or Neck)","enrollment":259},{"nctId":"NCT02802943","phase":"PHASE2","title":"iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2016-10-05","conditions":"Leukemia, Chronic Lymphatic","enrollment":56},{"nctId":"NCT04219358","phase":"PHASE1","title":"Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis","status":"TERMINATED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-03-23","conditions":"Actinic Cheilitis","enrollment":49},{"nctId":"NCT00585247","phase":"NA","title":"Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2006-11","conditions":"Port Wine Stain","enrollment":27},{"nctId":"NCT00142454","phase":"PHASE1","title":"NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2005-08-24","conditions":"Malignant Melanoma","enrollment":9},{"nctId":"NCT01808820","phase":"PHASE1","title":"Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma","status":"COMPLETED","sponsor":"Macarena De La Fuente, MD","startDate":"2013-08-21","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":20},{"nctId":"NCT04083157","phase":"PHASE2, PHASE3","title":"Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-08-12","conditions":"Inflammatory Bowel Diseases, Hepatitis B","enrollment":104},{"nctId":"NCT05314127","phase":"PHASE2","title":"Efficacy of Tazarotene in Treatment of Verruca Plana","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-04-15","conditions":"Warts Flat","enrollment":80},{"nctId":"NCT05315024","phase":"NA","title":"Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-30","conditions":"Influenza","enrollment":72},{"nctId":"NCT00189280","phase":"PHASE3","title":"Aldara for the Treatment of Large and/or Multiple sBCC","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2003-05","conditions":"Carcinoma, Basal Cell","enrollment":111},{"nctId":"NCT01453179","phase":"PHASE4","title":"Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2011-10","conditions":"Actinic Keratosis","enrollment":221},{"nctId":"NCT00189267","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2002-11","conditions":"Actinic Keratosis","enrollment":45},{"nctId":"NCT00189293","phase":"PHASE4","title":"Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2005-06","conditions":"Genital Warts","enrollment":128},{"nctId":"NCT00761371","phase":"PHASE4","title":"Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2002-08","conditions":"Warts","enrollment":52},{"nctId":"NCT00294320","phase":"PHASE3","title":"Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2006-02","conditions":"Actinic Keratosis","enrollment":12},{"nctId":"NCT00189241","phase":"PHASE3","title":"A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2001-02","conditions":"Basal Cell Carcinoma","enrollment":160},{"nctId":"NCT00777127","phase":"PHASE4","title":"Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2008-12","conditions":"Actinic Keratosis","enrollment":258},{"nctId":"NCT00189254","phase":"","title":"A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2005-04","conditions":"Actinic Keratoses","enrollment":72},{"nctId":"NCT04842422","phase":"PHASE4","title":"Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2021-04-16","conditions":"Actinic Keratoses","enrollment":48},{"nctId":"NCT05146895","phase":"NA","title":"A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts","status":"UNKNOWN","sponsor":"First Hospital of China Medical University","startDate":"2018-10-20","conditions":"Human Papilloma Virus","enrollment":60},{"nctId":"NCT01421017","phase":"PHASE1, PHASE2","title":"Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2011-08-19","conditions":"Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":31},{"nctId":"NCT04279535","phase":"EARLY_PHASE1","title":"Topical Vitamin C for Treatment of Basal Cell Cancer","status":"COMPLETED","sponsor":"Center for Biomedical Research, Inc.","startDate":"2018-03-01","conditions":"Basal Cell Carcinoma","enrollment":25},{"nctId":"NCT02242929","phase":"PHASE3","title":"Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2016-01","conditions":"Nodular Basal Cell Carcinoma","enrollment":145},{"nctId":"NCT05028322","phase":"PHASE2","title":"Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2021-11-01","conditions":"Cirrhosis, Liver, Vaccination Failure, HBV","enrollment":60},{"nctId":"NCT03982004","phase":"PHASE1","title":"Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer","enrollment":1},{"nctId":"NCT04859361","phase":"NA","title":"Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ","status":"UNKNOWN","sponsor":"University Medical Centre Maribor","startDate":"2018-11-20","conditions":"Intraepithelial Neoplasia, Cervical","enrollment":104},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT02301494","phase":"NA","title":"Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma","status":"WITHDRAWN","sponsor":"Rochester General Hospital","startDate":"2020-04","conditions":"Mycosis Fungoides","enrollment":""},{"nctId":"NCT01861535","phase":"PHASE3","title":"Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2013-06","conditions":"Vulvar Intraepithelial Neoplasia","enrollment":110},{"nctId":"NCT03233412","phase":"PHASE2","title":"Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions","status":"COMPLETED","sponsor":"Barretos Cancer Hospital","startDate":"2018-01-01","conditions":"High Grade Intraepithelial Neoplasia, Cervix Cancer","enrollment":90},{"nctId":"NCT03914417","phase":"PHASE2","title":"Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2013-01","conditions":"Actinic Keratosis","enrollment":21},{"nctId":"NCT02404389","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-03-05","conditions":"Actinic Keratosis","enrollment":82},{"nctId":"NCT02482428","phase":"PHASE2","title":"Efficacy and Tolerability of Topical LFX453 for External Genital Warts","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-12","conditions":"External Genital Warts","enrollment":88},{"nctId":"NCT01686152","phase":"PHASE3","title":"Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2012-09","conditions":"Actinic Keratosis","enrollment":589},{"nctId":"NCT03760250","phase":"PHASE2","title":"Imiquimod for Preventing Keloid Recurrence","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2019-02-05","conditions":"Keloid","enrollment":6},{"nctId":"NCT03289260","phase":"PHASE3","title":"Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2021-11-15","conditions":"Anogenital Human Papillomavirus Infection, Condyloma Anal","enrollment":200},{"nctId":"NCT00801320","phase":"NA","title":"Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-09","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":100},{"nctId":"NCT00948428","phase":"PHASE3","title":"Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2008-05","conditions":"Actinic Keratoses","enrollment":462},{"nctId":"NCT02293707","phase":"PHASE2","title":"A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Laboratoires Leurquin Mediolanum","startDate":"2014-11","conditions":"Prostate Cancer","enrollment":99},{"nctId":"NCT04072900","phase":"PHASE1","title":"A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-04-21","conditions":"Melanoma (Skin)","enrollment":30},{"nctId":"NCT02224599","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies","status":"TERMINATED","sponsor":"Kiromic BioPharma Inc.","startDate":"2017-07-28","conditions":"Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer","enrollment":3},{"nctId":"NCT00118313","phase":"PHASE1","title":"Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma","status":"COMPLETED","sponsor":"Craig L Slingluff, Jr","startDate":"2004-11-04","conditions":"Melanoma (Skin)","enrollment":""},{"nctId":"NCT01400672","phase":"PHASE1","title":"Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-07-17","conditions":"Diffuse Intrinsic Pontine Glioma","enrollment":8},{"nctId":"NCT01678352","phase":"EARLY_PHASE1","title":"Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas","status":"COMPLETED","sponsor":"Frank Lieberman","startDate":"2012-10","conditions":"High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma","enrollment":19},{"nctId":"NCT03472976","phase":"PHASE1","title":"H5N1 With or Without Topical Aldara in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-06-13","conditions":"Avian Influenza, Influenza Immunisation","enrollment":50},{"nctId":"NCT03901690","phase":"PHASE3","title":"Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study","status":"UNKNOWN","sponsor":"Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri","startDate":"2019-08-27","conditions":"Genital Wart Virus Infection","enrollment":102},{"nctId":"NCT02385188","phase":"PHASE3","title":"Topical 5% Imiquimod Cream for Vulvar Paget's Disease","status":"COMPLETED","sponsor":"University Medical Center Nijmegen","startDate":"2015-05","conditions":"Paget Disease, Extramammary","enrollment":25},{"nctId":"NCT02120898","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2013-10-10","conditions":"Actinic Keratosis","enrollment":467},{"nctId":"NCT02362152","phase":"","title":"The Real Life Topical Field Treatment of Actinic Keratosis Study","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-07","conditions":"Actinic Keratosis","enrollment":1168},{"nctId":"NCT02276300","phase":"PHASE1","title":"HER2-Peptide Vaccination of Patients With Solid Tumors","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2014-12","conditions":"Gastric Cancer, Breast Cancer","enrollment":2},{"nctId":"NCT03307902","phase":"PHASE2, PHASE3","title":"ID HBV Vaccination With Imiquimod in OBI","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-10-01","conditions":"Hepatitis B","enrollment":120},{"nctId":"NCT02621112","phase":"PHASE2, PHASE3","title":"HBV Vaccine in Renal Failure Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-01","conditions":"Renal Failure","enrollment":94},{"nctId":"NCT01088737","phase":"PHASE2, PHASE3","title":"Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna","status":"UNKNOWN","sponsor":"Medical University of Graz","startDate":"2011-01","conditions":"Lentigo Maligna","enrollment":60},{"nctId":"NCT03116659","phase":"EARLY_PHASE1","title":"CTCL Directed Therapy","status":"UNKNOWN","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2018-02-01","conditions":"Lymphoma, T-Cell, Cutaneous","enrollment":8},{"nctId":"NCT00685750","phase":"NA","title":"Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2008-04-28","conditions":"Lung Cancer, Non-Small Cell","enrollment":88}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"HAEMOGLOBIN DECREASED"},{"count":3,"reaction":"PLATELET COUNT DECREASED"},{"count":2,"reaction":"APPLICATION SITE ERYTHEMA"},{"count":2,"reaction":"APPLICATION SITE PAIN"},{"count":2,"reaction":"DEHYDRATION"},{"count":2,"reaction":"DRUG ADMINISTERED AT INAPPROPRIATE SITE"},{"count":2,"reaction":"INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION"},{"count":2,"reaction":"PALPITATIONS"},{"count":2,"reaction":"PYREXIA"},{"count":2,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Aldara (Imiquimod)","genericName":"Aldara (Imiquimod)","companyName":"MEDA Pharma GmbH & Co. KG","companyId":"meda-pharma-gmbh-co-kg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat viral infections and skin cancers. Used for Genital warts (external), Actinic keratosis, Superficial basal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}